Can Dementia Really Be Transmitted Through Blood? What the New Lancet Paper Actually Says

Can Alzheimer's disease be transmitted through a blood transfusion?

A paper published in The Lancet on August 22, 2026, generated exactly that headline by discussing the possibility that amyloid-beta protein that accumulates abnormally in Alzheimer's disease and cerebral amyloid angiopathy (CAA) might be transmitted through blood products under specific circumstances.¹ That sounds alarming, but it is also very easy to misunderstand what was actually published.

The new paper did not demonstrate that Alzheimer's disease is transmitted through blood.¹ Researchers did not administer blood from an Alzheimer's patient to a healthy recipient and watch the disease develop, nor did they identify a cohort of transfusion recipients who later developed biomarker-confirmed Alzheimer's. In fact, the paper is not a new clinical trial or observational study; it is a Viewpoint.¹ The authors reviewed several unusual findings from prior research and argued that together they raise a question worth taking seriously: could amyloid-beta pathology sometimes be transmitted through blood transfusion, and if so, should we do more to understand and prevent it?¹

First, What Exactly Are We Talking About Transmitting?

This distinction is essential. Dementia, Alzheimer's disease, amyloid-beta pathology, and cerebral amyloid angiopathy are related concepts, but they are not interchangeable.

Dementia is a clinical syndrome, a decline in cognitive abilities severe enough to interfere with everyday functioning, and many different diseases can cause it. Alzheimer's disease is one specific disease associated with both amyloid-beta and tau pathology. Cerebral amyloid angiopathy, or CAA, occurs when amyloid-beta accumulates in blood vessel walls in the brain and can lead to brain hemorrhages.

The Lancet paper is specifically examining whether amyloid-beta pathology could potentially be transmitted through blood products.¹

That distinction matters. Demonstrating that an amyloid-beta seed can move between people would be scientifically remarkable, but it would not by itself demonstrate that “dementia is transmissible.” The question is what happens after that seed arrives, and whether the cascade necessary to produce CAA, Alzheimer's pathology, cognitive impairment, or dementia actually follows.

Why Scientists Are Even Asking This Question

The concern did not appear out of nowhere. Over the past decade, evidence has accumulated that amyloid-beta pathology can, under extraordinarily rare circumstances, be acquired from another human being. One of the primary clues came from individuals who received cadaveric pituitary-derived human growth hormone decades ago.² That practice was discontinued after certain preparations were found to transmit Creutzfeldt-Jakob disease (CJD), a true prion disease. Years later, investigators examined archived growth-hormone batches and discovered they also contained amyloid-beta capable of seeding pathology experimentally.

Some recipients of those preparations developed substantial amyloid pathology and early cognitive symptoms decades later.² The initial 2024 report was not universally accepted as proof of iatrogenic Alzheimer's disease. Critics noted that several of the patients lacked the combination of amyloid and extensive tau pathology required to firmly establish Alzheimer's disease and argued that alternative explanations for their cognitive impairment remained possible.³

That debate changed somewhat in 2026. Researchers reported the autopsy of another former cadaveric growth-hormone recipient who had developed dementia beginning at age 47. His brain showed not merely amyloid deposition, but the highest level of Alzheimer's disease neuropathologic change, widespread amyloid plaques, very severe cerebral amyloid angiopathy, and Braak stage VI tau pathology.⁴

This still does not establish that Alzheimer's can be transmitted through blood. But it strengthens the evidence for a narrower and more unusual proposition: under certain historical medical exposure conditions, externally introduced amyloid-beta seeds may initiate pathology that ultimately develops into the full neuropathologic picture of Alzheimer's disease.

This Historical Exposure Was Nothing Like a Blood Transfusion

Crucially, those historical exposures look nothing like receiving a modern blood transfusion. These individuals received repeated treatments derived from pooled human cadaveric tissue over several years via a medical process abandoned long ago.² They did not acquire it through everyday contact, nor did they receive an ordinary blood transfusion. The researchers themselves have repeatedly emphasized that there is no evidence Alzheimer's disease can be transmitted through normal interpersonal contact, making terms like “contagious” fundamentally misleading.^1,2 Influenza is contagious; protein seeding following specialized cadaveric tissue processing is an iatrogenic transmission under extreme conditions.

So Where Does Blood Come Into This?

This brings us to where blood enters the discussion. The Lancet Viewpoint points to a large Scandinavian study published in JAMA in 2023 involving over one million red blood cell transfusion recipients.^1,5 Researchers looked at recipients of blood from donors who later suffered multiple spontaneous brain hemorrhages, a clinical pattern that can be associated with CAA.⁵ In Sweden and Denmark, recipients of blood from donors who later suffered multiple brain hemorrhages were themselves more likely to experience a spontaneous brain hemorrhage, with adjusted hazard ratios of 2.73 and 2.32, respectively. Importantly, donors who later had only a single spontaneous hemorrhage did not show this association.⁵

The relative risk sounds dramatic, but the underlying exposure was exceptionally uncommon. Only about 0.1% of recipients had received blood from a donor who later developed multiple spontaneous brain hemorrhages (862 people in Sweden and 448 in Denmark). The association was driven by 18 recipient hemorrhages in the Swedish cohort and six in the Danish cohort.⁵

That result deserves attention, but it also has important limitations. The researchers did not confirm that donors or recipients had CAA, they did not measure amyloid-beta transmission, and they did not demonstrate the transmission of Alzheimer's or dementia.⁵ Brain hemorrhage was simply used as an indirect proxy. As the study's authors explicitly noted, the analysis was exploratory, the events were rare, and residual confounding could not be excluded.⁵ It is an intriguing signal, not proof of a mechanism.

There Is Also Evidence Pointing the Other Way

Furthermore, evidence pointing the other way receives far less attention than it warrants. A 2016 Scandinavian cohort study specifically examined whether people receiving blood from donors who later developed neurodegenerative diseases were more likely to develop those same conditions.⁶ The hazard ratio for Alzheimer's disease among recipients was 0.99, essentially zero difference.⁶ While a single observational study cannot guarantee zero risk due to potential long incubation periods or diagnostic limitations, any serious discussion of transfusion safety must account for the large datasets that show no effect.¹

Could Amyloid Actually Travel From Blood Into the Brain?

From a biological standpoint, the concept is not impossible. Animal studies show that amyloid-beta introduced intravenously can promote amyloid deposition in the brain under experimental conditions.¹ However, biological plausibility is not the same thing as demonstrating a clinically meaningful risk in humans.

For a blood transfusion to cause Alzheimer's disease, one plausible mechanism would require a donor to have active seeds in a transfusable component that survive processing and storage, cross or signal across the blood-brain barrier, evade host clearance mechanisms, and initiate a cascade that takes decades to express clinically. We currently do not know how often, if ever, that entire chain of events occurs in modern medicine.¹

Should People Be Afraid to Receive Blood?

The current evidence does not support avoiding or refusing a medically indicated blood transfusion because of concern about Alzheimer's disease. Transfusions are life-saving interventions, and nothing in the current literature suggests that the known benefits of an indicated transfusion are outweighed by a theoretical risk of neurodegenerative disease.¹ The authors of the Lancet paper are not advising patients to refuse blood; they are arguing that because amyloid transmission appears biologically possible under rare historical conditions, medicine should actively investigate contemporary blood safety rather than rely on assumptions.¹

The Most Accurate Headline Is Also the Least Dramatic

Ultimately, researchers did not discover that dementia spreads through blood.¹ What we have instead are several pieces of evidence that are important, but not yet connected.

We have increasingly persuasive evidence that amyloid-beta pathology can be transmitted between humans under extraordinary historical medical circumstances involving cadaver-derived tissue.^2,4 We now have neuropathologic evidence that, in at least one such recipient, the eventual result included the full pathologic features of Alzheimer's disease.⁴ And separately, we have an epidemiologic signal suggesting that something associated with recurrent brain hemorrhage may have passed between certain blood donors and recipients.⁵

What we do not have is evidence connecting those observations.

Researchers have not demonstrated that amyloid-beta was present in the implicated donor blood, that it survived transfusion, that it entered or influenced the recipient's brain, or that it caused CAA, Alzheimer's disease, or dementia. We also have large observational data in which receiving blood from donors who later developed Alzheimer's disease was not associated with an increased risk of developing Alzheimer's disease.⁶

So the honest conclusion is neither blood transfusions can transmit Alzheimer's disease, nor there is nothing here.

There is something here.

It is a biologically plausible hypothesis supported by enough unusual evidence to justify taking it seriously, and not enough evidence to conclude that modern blood transfusions transmit Alzheimer's disease.

That distinction may not make the most dramatic headline. But right now, it is where the science actually stands.

References

1. Banerjee G, Farmer SF, Hyare H, et al. Risk of transmission of amyloid pathology via transfused blood products. Lancet. 2026. doi:10.1016/S0140-6736(26)00767-1
2. Banerjee G, Samra SS, Adams ME, et al. Iatrogenic Alzheimer's disease in recipients of cadaveric pituitary-derived growth hormone. Nat Med. 2024;30(2):394-402. doi:10.1038/s41591-023-02729-2
3. Leschek EW, Mills JL, et al. Insufficient evidence for an association between iatrogenic Alzheimer's disease and cadaveric pituitary-derived growth hormone. Alzheimers Dement. 2024. doi:10.1002/alz.14127
4. Banerjee G, Mok TH, Hyare H, et al. High-level Alzheimer disease neuropathological change following iatrogenic exposure. JAMA Neurol. 2026;83(5):435-441. doi:10.1001/jamaneurol.2026.0437
5. Zhao J, Rostgaard K, Lauwers E, et al. Intracerebral hemorrhage among blood donors and their transfusion recipients. JAMA. 2023;330(10):941-950. doi:10.1001/jama.2023.14445
6. Edgren G, Hjalgrim H, Rostgaard K, et al. Transmission of neurodegenerative disorders through blood transfusion: a cohort study. Ann Intern Med. 2016;165(5):316-324. doi:10.7326/M15-2421